Alejandro Godoy

Jan 2, 2024 | onlinecjc.ca | Alejandro Godoy |Noel C. Chan |John Eikelboom |Jack Hirsh |Vinai Bhagirath

Clinical trials are performed with the aim of improving patient care. Occasionally, the results are sufficiently convincing to change clinical practice. The recently published FRAIL-AF trial reported that patients with atrial fibrillation (AF) and frailty who have stable international normalized ratio (INR) would be safer to remain on vitamin K antagonists (VKAs) rather than being switched to a direct oral anticoagulant (DOAC),1.